^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCARH125

    i
    Other names: MCARH125
    Associations

    News

    Trials
    Company:
    Memorial Sloan-Kettering Cancer Center
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    |
    MCARH109 • MCARH125
    9ms
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 15
    Enrollment closed • Enrollment change
    |
    SDC1 (Syndecan 1)
    |
    MCARH109 • MCARH125
    over1year
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    SDC1 (Syndecan 1)
    |
    MCARH109 • MCARH125